Clinical Trial Update: Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer [Phase 1]

View source ↗

Summary

This document describes a Phase 1 trial evaluating the combination of niraparib and copanlisib in patients with recurrent endometrial, ovarian, primary peritone…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer
• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Copanlisib (copanlisib)
• Niraparib (Niraparib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation | Phase 1 | Status: ACTIVE_NOT_RECRUITING